EADV 2022: Apremilast Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Children
Psoriasis that was inadequately controlled by or intolerant to topical therapy improved for children ages 6 to 17 years, with no new safety signals identified
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.